(NASDAQ: TXG) 10x Genomics's forecast annual revenue growth rate of 3.91% is not forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 9.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.1%.
10x Genomics's revenue in 2026 is $642,823,000.On average, 18 Wall Street analysts forecast TXG's revenue for 2026 to be $79,109,305,767, with the lowest TXG revenue forecast at $75,335,504,184, and the highest TXG revenue forecast at $83,703,276,821. On average, 18 Wall Street analysts forecast TXG's revenue for 2027 to be $85,008,904,857, with the lowest TXG revenue forecast at $79,500,227,664, and the highest TXG revenue forecast at $92,154,088,423.
In 2028, TXG is forecast to generate $92,446,641,085 in revenue, with the lowest revenue forecast at $83,493,763,124 and the highest revenue forecast at $101,275,599,359.